| Identification | Back Directory | [Name]
N-[6-Methoxy-4-[[1-(1-methylethyl)-4-piperidinyl]amino]-7-[3-(1-pyrrolidinyl)propoxy]-2-quinolinyl]-2-propenamide | [CAS]
2866408-21-9 | [Synonyms]
N-[6-Methoxy-4-[[1-(1-methylethyl)-4-piperidinyl]amino]-7-[3-(1-pyrrolidinyl)propoxy]-2-quinolinyl]-2-propenamide | [Molecular Formula]
C28H41N5O3 | [MOL File]
2866408-21-9.mol | [Molecular Weight]
495.66 |
| Chemical Properties | Back Directory | [Boiling point ]
689.9±55.0 °C(Predicted) | [density ]
1.170±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
11.75±0.43(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC50 values of 100 nM (G9a) and 140 nM (GLP), and Kd values of 44 nM (G9a) and 46 nM (GLP). MS8511 reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader?Willi syndrome (PWS)[1]. | [IC 50]
G9a: 100 nM (IC50); G9a: 44 nM (Kd); GLP: 140 nM (IC50); GLP: 46 nM (Kd) | [References]
[1] Kwang-Su Park, et al. Discovery of the First-in-Class G9a/GLP Covalent Inhibitors. J Med Chem. 2022 Jun 28. DOI:10.1021/acs.jmedchem.2c00652 |
|
|